New to oneAMYLOIDOSISvoice? Activate your membership!
Whether you’re a first-time visitor or someone already well familiar with our growing collection of the best and most trustworthy amyloidosis resources from across the web, there’s a lot more to oneAMYLOIDOSISvoice. But it’s exclusively available to our registered members. Registering as a member is quick and easy, and best of all, it’s FREE. We hope you’ll jump in and explore all that oneAMYLOIDOSISvoice has to offer.
|Access to Trusted Resources & Diagnosis Educator sections
|Access to Clinical Trial Locator
|Access to Social Wall (Community Discussion)
|rareTeams Private Groups
|Weekly Activity E-mails
|Bookmarking of Resources & Conversations
|Customized Member Profile
Join the conversation
The Social Wall is the heart of oneAMYLOIDOSISvoice — where you can share your thoughts, ask questions and discuss the latest amyloidosis news and research, as well as post photos, videos, or links.
Create your free member account or log in to join the conversation!
More helpful articles
- Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
- Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
- How Did Transthyretin Amyloid Cardiomyopathy Progress in Patients Who Took Placebo in the Study ATTR-ACT? A Plain Language Summary
- Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
News & Resources
What Initial Steps Can Healthcare Providers Take When Amyloidosis Is Suspected?
What Are the Unique Symptoms of Different Types of Amyloidosis?
- WtATTR Amyloidosis - Symptoms and Prevalence
- hATTR Amyloidosis - Symptoms and Prevalence
- AL Amyloidosis - Symptoms and Prevalence
- AA Amyloidosis - Symptoms and Prevalence
- Clinical Features
- Types and Clinical Presentation
- Wild-Type Vs Hereditary ATTR-CM
- Wild Type Transthyretin Amyloidosis ATTRwt - An Overview
- Wild Type ATTR Amyloidosis
- Wild-Type ATTR- Fact Sheet
The Onevoice Difference
Everything you’ll find on this site is curated by professional researchers who are guided by our councils of healthcare professionals, advocates, patients, and caregivers. We provide only the best, mosttrusted rare-disease resources.
This onevoice site is maintained in collaboration with Amyloidosis Support Groups. They help us keep up-to-date with the fast-changing world of rare disease and ensure that we always meet the needs of the community.
Safe Community Space
Our Social Wall and private rareTeams groups are members-only features, with the aim of providing a safe, secure space for community-driven conversations, moderated by a disease-knowledgeable community leader.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
oneAMYLOIDOSISvoice Working Group
Katie Agre, MS, LCGCLicensed Genetic Counselor
Department of Clinical Genomics
Cara A. Rosenbaum, MDAssistant Professor of Medicine
Division of Hematology
and Medical Oncology
Weill Cornell Medicine
New York-Presbyterian Hospital
Jeffrey Allan Zonder, MDProfessor
Department of Oncology
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Sara Horst, MD, MPHAssociate Professor
Division of Gastroenterology, Hepatology, & Nutrition
Vanderbilt University Medical Center
1030C MRB IV, 2215 Garland Avenue
Chafic Karam, MDNeurologist
Penn Neuroscience Center
Perelman Center for Advanced Medicine
Kevin Michael Alexander, MDInstructor, Cardiovascular Institute
Kelsey Barrell, MDAssistant Professor
Department of Neurology, University of Utah